Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

22%
Genetic Cohort Participants
Enrollmen Goal: 600

18%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment Goal: 400

100%
Control Participants
Enrollment Goal: 200

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment Goal: 100

Last Update: April 6, 2015

 

More about study cohorts >

Welcome

Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

SWEDDs and Nonmotor Symptoms Publication

In a recent paper in Movement Disorders, researchers sought to better understand SWEDDs compared to people with Parkinson’s and healthy controls (HCs) by comparing the nonmotor symptoms for each group using the PPMI baseline data. Certain symptoms, like orthostatic hypotension, were found to be more common in SWEDDs than in PD participants.


Genetic and Prodromal Cohort Data Now Live

The PPMI prodromal cohort, genetic cohort, and genetic registry data is now live and available for download in the PPMI database. Read more about these cohorts and access this data.


Results Published on Cognitive Performance and Neuropsychatric Symptoms

In a paper published in Movement Disorders, Weintraub, et al. investigate the prevalence of cognitive impairment and neuropsychiatric symptoms (NPS), such as depression, apathy, and anxiety, in early, unmedicated people with Parkinson’s compared with healthy controls (HCs) using the PPMI baseline data.


PPMI at AAN 2015

PPMI is headed to the American Academy of Neurology (AAN) 2015 Annual Meeting, taking place in Washington D.C. from April 18 through April 25. Top players in neurology will come together to learn about the latest in research, showcased through presentations and posters, including several featuring PPMI data.


Whole Exome Sequencing Data Now Available

The PPMI Genetics Core has just made their whole exome sequencing data live in the PPMI database. This sequencing targeted 201,121 Exons, UTRs, and miRNA in DNA from whole-blood from the original PPMI cohort of over 600 PD, SWEDD, and control subjects. Read more about the analysis and learn how to access the data.


Learn More